M&T Bank Corp lessened its stake in Teleflex Incorporated (NYSE:TFX) by 1.4% during the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 5,672 shares of the medical technology company’s stock after selling 81 shares during the quarter. M&T Bank Corp’s holdings in Teleflex were worth $1,179,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently made changes to their positions in the company. OLD Mutual Customised Solutions Proprietary Ltd. grew its stake in shares of Teleflex by 200.0% during the 1st quarter. OLD Mutual Customised Solutions Proprietary Ltd. now owns 900 shares of the medical technology company’s stock valued at $174,000 after buying an additional 600 shares during the period. Campbell & CO Investment Adviser LLC acquired a new stake in shares of Teleflex during the 2nd quarter worth $200,000. Calamos Advisors LLC acquired a new stake in shares of Teleflex during the 2nd quarter worth $206,000. Harvey Capital Management Inc. acquired a new stake in shares of Teleflex during the 2nd quarter worth $207,000. Finally, Advisor Partners LLC acquired a new stake in shares of Teleflex during the 2nd quarter worth $212,000. Institutional investors own 89.75% of the company’s stock.

WARNING: This piece was originally reported by Watch List News and is owned by of Watch List News. If you are reading this piece on another domain, it was illegally copied and reposted in violation of U.S. and international copyright & trademark law. The correct version of this piece can be viewed at https://www.watchlistnews.com/teleflex-incorporated-tfx-shares-sold-by-mt-bank-corp/1602985.html.

Teleflex Incorporated (NYSE:TFX) opened at 241.97 on Monday. The firm has a market cap of $10.90 billion, a PE ratio of 46.27 and a beta of 1.07. Teleflex Incorporated has a 52 week low of $136.53 and a 52 week high of $242.61. The firm’s 50 day moving average price is $216.57 and its 200-day moving average price is $205.08.

Teleflex (NYSE:TFX) last announced its quarterly earnings results on Thursday, August 3rd. The medical technology company reported $2.04 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $1.91 by $0.13. Teleflex had a return on equity of 16.12% and a net margin of 12.36%. The business had revenue of $528.60 million during the quarter, compared to analysts’ expectations of $518.98 million. During the same quarter in the previous year, the business posted $1.89 EPS. The firm’s quarterly revenue was up 11.6% compared to the same quarter last year. On average, analysts forecast that Teleflex Incorporated will post $8.28 EPS for the current year.

The firm also recently disclosed a quarterly dividend, which was paid on Friday, September 15th. Investors of record on Tuesday, August 15th were given a dividend of $0.34 per share. This represents a $1.36 annualized dividend and a yield of 0.56%. The ex-dividend date of this dividend was Friday, August 11th. Teleflex’s payout ratio is presently 26.00%.

In other Teleflex news, Director Stephen K. M.D. Klasko sold 200 shares of Teleflex stock in a transaction that occurred on Friday, September 1st. The shares were sold at an average price of $211.75, for a total value of $42,350.00. Following the completion of the sale, the director now directly owns 8,080 shares in the company, valued at $1,710,940. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. 2.39% of the stock is currently owned by company insiders.

A number of research analysts recently weighed in on the company. Jefferies Group LLC reiterated a “buy” rating and issued a $230.00 target price on shares of Teleflex in a report on Thursday, August 3rd. BidaskClub lowered Teleflex from a “hold” rating to a “sell” rating in a research note on Tuesday, August 8th. Stephens restated a “buy” rating and issued a $270.00 price objective (up from $230.00) on shares of Teleflex in a report on Monday, September 25th. Needham & Company LLC restated a “buy” rating on shares of Teleflex in a report on Friday, August 4th. Finally, Deutsche Bank AG reaffirmed a “buy” rating and issued a $238.00 price objective (up from $220.00) on shares of Teleflex in a research note on Wednesday, August 9th. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and eight have given a buy rating to the stock. Teleflex has a consensus rating of “Buy” and a consensus price target of $260.75.

Teleflex Company Profile

Teleflex Incorporated is a provider of medical technology products. The Company designs, develops, manufactures and supplies single-use medical devices used by hospitals and healthcare providers for diagnostic and therapeutic procedures in critical care and surgical applications. The Company operates through six segments: Vascular North America; Anesthesia North America; Surgical North America; Europe, the Middle East and Africa (EMEA); Asia, and Original Equipment Manufacturer (OEM).

Institutional Ownership by Quarter for Teleflex (NYSE:TFX)

Receive News & Ratings for Teleflex Incorporated Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teleflex Incorporated and related companies with Analyst Ratings Network's FREE daily email newsletter.